Every story stays here. Filter by topic, search older headlines, and save favorites to your member record. Educational notes only — not medical advice.
Study (dose-response meta-analysis of prospective cohorts). Liu and colleagues report in Family Medicine and Community Health (doi 10.1136/fmch-2026-003925) on 51 cohorts and 8,819,894 adults whose mean ages ran from 23 to 77, followed 2 to 32 years. Higher ultra-processed food intake was associated with higher risk of cardiovascular events (24%), metabolic syndrome or diabetes (24%), death from any cause (18%), and high blood pressure (11%), among other outcomes. Each extra 100 g per day tracked a 14% higher cardiovascular-event risk and a 2% higher metabolic syndrome or diabetes risk. Diets were self-reported, and the rest of lifestyle is hard to fully adjust for. Association, not a treatment claim. Educational nutrition notes.
Study (people and animal models). W. David Arnold and colleagues report in The Journal of Clinical Investigation (doi 10.1172/JCI190646; paper 9 July 2026, news release 22 September 2026) that the neuromuscular junction gets less reliable with age as the muscle sodium-channel protein NaV1.4 falls. Sarcopenia affects nearly half of adults over 80. Partially blocking the chloride channel ClC-1 made aging muscle more responsive to nerve signals and improved strength in an animal model. A separate ClC-1 candidate, ignaseclant, has been studied in Charcot-Marie-Tooth disease, not as an approved treatment for ordinary age-related weakness. Educational aging notes, not a drug recommendation.
A sweeping review of more than 153,000 adults found that calcium and vitamin D supplements, alone or together, do little to prevent fractures or falls in most older people. Researchers say the findings challenge routine supplementation for prevention and point instead toward strategies such as balance and resistance exercise.
Study (animal). Joseph Bass, Anneke Thorne, and colleagues report work headed for PNAS (doi 10.1073/pnas.2618845123; Northwestern note 21 September 2026). A short RNA strand silenced ZFP423, a brake on turning white fat into beige fat, and the lab says that raised thermogenesis. In mice, the RNA approach improved glucose tolerance and reduced body fat without lean-mass loss on its own. Combined with the GLP-1 drug semaglutide, mice lost more weight and fat than with semaglutide alone and kept more lean mass: about 5.5% lean-mass loss versus about 10%, and about 4 grams of body fat versus nearly 8 grams. Northwestern has filed a provisional patent; Bass and Thorne are listed as inventors. This is a mouse experiment, not a human product, and it is not a reason to start, stop, or swap a prescribed GLP-1 drug. Educational supplement parallel (not a replacement): When headlines discuss GLP-1 medicines and aging, people often research food-first fiber or bitter-botanical “pathway support” formulas. Those are not semaglutide, not compounded GLP-1, and not a substitute for a prescribed GLP-1 drug. Mouse or marketing claims are hype until human outcome data exist. Weakly evidenced. Store: /store/glp1-pathway-support. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
Study (animal). Penn State researchers in the Drew Lab report in Proceedings of the National Academy of Sciences (news release 21 September 2026) that abdominal-muscle contraction, from movement, exercise, or even a cough, raises pressure in vessels that reach the brain through the spinal column. In mice that pressure produced ultrafast constriction of major brain veins, within about a tenth of a second, and a brief rise in blood flow. Arterial constriction is slower, on the order of a second or more. Preclinical physiology, not a human workout prescription and not a migraine treatment. Educational exercise notes.
Study (target-trial emulation). Yan Xie, Taeyoung Choi, and Ziyad Al-Aly report in BMJ Medicine (2026; 5:e002150; doi 10.1136/bmjmed-2025-002150) on 333,687 U.S. veterans with type 2 diabetes followed for up to three years. Staying on a GLP-1 medicine (semaglutide or tirzepatide) continuously was linked to an 18% lower risk of heart attack, stroke, or death than sulfonylurea use. Stopping for one year without restarting tracked a 14% higher risk versus staying on the GLP-1; two years off tracked 22% higher. A six-month gap before restarting still weakened the benefit. About 26% stopped outright and about 23% had a gap of at least six months. Observational. These are prescribed medicines, not longevity supplements. Do not start or stop one because of a headline. Educational notes, not medical advice. Educational supplement parallel (not a replacement): When headlines discuss GLP-1 medicines and aging, people often research food-first fiber or bitter-botanical “pathway support” formulas. Those are not semaglutide, not compounded GLP-1, and not a substitute for a prescribed GLP-1 drug. Mouse or marketing claims are hype until human outcome data exist. Weakly evidenced. Store: /store/glp1-pathway-support. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
Study (cross-sectional; JAMA Network Open 2024, recirculated 21 September 2026). Dorothy Chiu, Elissa Epel, Barbara Laraia and colleagues scored 342 Black and White women (mean age 39.2) on Mediterranean, AHEI, and an epigenetic-nutrient index plus added sugar. Better diet scores tracked younger GrimAge2; each extra gram of added sugar tracked older GrimAge2 even after diet quality. Cross-section, not a feeding trial. Educational nutrition notes, not a sugar-tax or supplement claim.
Study (longitudinal, genetically informed). Anni Pitkänen and University of Jyväskylä colleagues report in the International Journal of Obesity (doi 10.1038/s41366-026-02194-0) on the Cardiovascular Risk in Young Finns Study. BMI was measured at ages 9–18, with ~40 years of follow-up and DNA-methylation clocks in adulthood. A polygenic BMI score plus Mendelian randomization suggested higher adolescent BMI may be causally linked to faster biological aging, partly via adult BMI. Observational genetics, not a diet trial. Educational aging notes, not a weight-loss prescription.
Study (small training trial, described in a 21 September 2026 UNC Nutrition Research Institute briefing). Abbie Smith-Ryan reported a six-week high-intensity resistance program in perimenopausal women: two ~30-minute sessions a week with significant strength gains plus signals for muscle quality and early bone changes. Briefing, not a large multicenter RCT; sample size not fully reported in the public note. Educational exercise notes for midlife women, not a menopause drug substitute.
Study (small human plus animal/cell). A Journal of Neuroinflammation paper reports 26 men with major depression had lower serum testosterone and higher IL-1β, IL-18, NLRP3, and P2X7 than controls. In testosterone-deficient models, androgen-receptor downregulation tracked hippocampal NLRP3 inflammation; testosterone replacement eased those markers in animals and an LPS cell model. Tiny clinical sample; not a depression trial in the clinic. Educational research notes, not a prescription for testosterone therapy.
Study (observational). Nicholas Koemel and Monash University colleagues report in the British Journal of Sports Medicine on 64,743 middle-aged adults followed about eight years (1,697 deaths; 502 cardiovascular). Among people logging fewer than 5,000 daily steps, a peak 30-minute cadence of about 80 steps per minute tracked 28% lower all-cause mortality versus a low-step, low-cadence group. Lowest overall risk sat around 7,500–10,000 steps with a peak cadence near 100. Association, not a step-count prescription. Educational exercise notes.
Ozempic and other GLP-1 medications can improve blood sugar, weight, and cardiovascular health, but researchers found little evidence that they also improve mental health, employment, marriage, or overall well-being. The findings suggest the drugs’ broader life effects may be subtler than their dramatic physical health benefits. Educational supplement parallel (not a replacement): When headlines discuss GLP-1 medicines and aging, people often research food-first fiber or bitter-botanical “pathway support” formulas. Those are not semaglutide, not compounded GLP-1, and not a substitute for a prescribed GLP-1 drug. Mouse or marketing claims are hype until human outcome data exist. Weakly evidenced. Store: /store/glp1-pathway-support. Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
VitaLonga is an educational longevity resource, not a pharmacy, clinic, or doctor. Content is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease (DSHEA). Supplements can interact with medications and are not appropriate in every pregnancy or health condition. Consult a licensed clinician, especially if you take medications, are pregnant or nursing, or have a diagnosed condition.
